(Q31161048)

English

Development and characterization of an antibody-labeled super-paramagnetic iron oxide contrast agent targeting prostate cancer cells for magnetic resonance imaging

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Development and characterization of an antibody-labeled super-paramagnetic iron oxide contrast agent targeting prostate cancer cells for magnetic resonance imaging (English)

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

1 reference

based on heuristic

inferred from title

4

object named as

Ingeborg Zehbe

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

author name string

David Bates

1

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Suraj Abraham

2

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Michael Campbell

3

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Laura Curiel

5

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

language of work or name

0 references

publication date

12 May 2014

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

9

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

5

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

e97220

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

copyright license

Creative Commons Attribution 4.0 International

12 May 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Detection of tumor markers in prostate cancer and comparison of sensitivity between real time and nested PCR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

The Asian-American E6 variant protein of human papillomavirus 16 alone is sufficient to promote immortalization, transformation, and migration of primary human foreskin keratinocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Integrin signaling in cancer cell survival and chemoresistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Retracted: Prostate Cancer Cell Lines under Hypoxia Exhibit Greater Stem-Like Properties

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Multifunctional nanoparticles for multimodal imaging and theragnosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Labeling of multiple cell lines using a new iron oxide agent for cell tracking by MRI.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Noninvasive cell-tracking methods

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

In vivo targeted delivery of nanoparticles for theranosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Prostate cancer targeting motifs: expression of αν β3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Activatable T₁ and T₂ magnetic resonance imaging contrast agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Nanoparticle-based theragnostics: Integrating diagnostic and therapeutic potentials in nanomedicine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

The immortalizing and transforming ability of two common human papillomavirus 16 E6 variants with different prevalences in cervical cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Quantitative MR imaging of targeted SPIO particles on the cell surface and comparison to flow cytometry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Other biomarkers for detecting prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Active and passive immunotherapy: vaccines and antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Technology insight: monoclonal antibody imaging of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Is prostate-specific membrane antigen a multifunctional protein?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Molecular magnetic resonance imaging with targeted contrast agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

In vitro studies of gadolinium-DTPA conjugated with monoclonal antibodies as cancer-specific magnetic resonance imaging contrast agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

In vivo studies of Gd-DTPA-monoclonal antibody and gd-porphyrins: potential magnetic resonance imaging contrast agents for melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

21 June 2018

Risk factors and quality of life for post-prostatectomy vesicourethral anastomotic stenoses.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0097220

21 January 2018

Induction of effective antitumor response after mucosal bacterial vector mediated DNA vaccination with endogenous prostate cancer specific antigen.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0097220

21 January 2018

Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0097220

21 January 2018

Targeting Metastatic Prostate Cancer With Radiolabeled Monoclonal Antibody J591 to the Extracellular Domain of Prostate Specific Membrane Antigen

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0097220

21 January 2018

Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0097220

21 January 2018

Effect of cell density on androgen regulation of the mRNA level of human prostatic acid phosphatase

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0097220

21 January 2018

Enhancement patterns of prostate cancer in dynamic MRI

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018298

31 October 2018

Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor: work in progress

1 reference

https://pubmed.ncbi.nlm.nih.gov/24819929

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Specific MR imaging of human lymphocytes by monoclonal antibody-guided dextran-magnetite particles

1 reference

https://pubmed.ncbi.nlm.nih.gov/24819929

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen

1 reference

https://pubmed.ncbi.nlm.nih.gov/24819929

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium

1 reference

https://pubmed.ncbi.nlm.nih.gov/24819929

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stability constants for Gd3+ binding to model DTPA-conjugates and DTPA-proteins: implications for their use as magnetic resonance contrast agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/24819929

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/24819929

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor

1 reference

https://pubmed.ncbi.nlm.nih.gov/24819929

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MRI contrast enhancement by Gd-DTPA-monoclonal antibody in 9L glioma rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/24819929

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gateways to clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/24819929

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24819929

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0097220

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

2014PLoSO...997220B

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31161048&oldid=2086923769"